Source comparison
Thymosin Alpha-1 for Vaccine Enhancement: Protocol Comparison
Standard 2-week protocol 1.6 mg SC twice weekly × 2 weeks First dose 48h pre-vaccine, continue 2 weeks post Elderly (≥65 years), immunosenescence +30–38% vs vaccine alone Most-studied protocol; balances efficacy and patient burden; suitable for outpatient sett
This comparison does not assign a generated winner or score.
- Standard 2-week protocol
- 1.6 mg SC twice weekly × 2 weeks
- First dose 48h pre-vaccine, continue 2 weeks post
- Elderly (≥65 years), immunosenescence
- +30–38% vs vaccine alone
- Most-studied protocol; balances efficacy and patient burden; suitable for outpatient settings
- Intensive 4-week protocol
- 1.6 mg SC twice weekly × 4 weeks
- First dose 48h pre-vaccine, continue 4 weeks post
- Transplant recipients, severe immunosuppression
- +45–60% vs vaccine alone
- Required for patients on calcineurin inhibitors or high-dose steroids; higher cumulative dose overcomes pharmacological suppression
- Single-dose adjuvant
- 1.6 mg SC single dose
- 24–48h pre-vaccine only
- Chronic viral infections (HBV, HCV, HIV)
- +15–25% vs vaccine alone
- Minimal benefit; insufficient to sustain Th1 response through memory cell differentiation phase; not recommended
- High-dose short protocol
- 3.2 mg SC twice weekly × 1 week
- 48h pre-vaccine, 72h post-vaccine
- Non-responders to prior vaccination attempts
- +40–50% in prior non-responders
- Experimental; used in salvage therapy for hepatitis B vaccine non-responders; higher incidence of injection site reactions
- Every protocol requires subcutaneous injection of pharmaceutical-grade thymosin alpha-1 reconstituted with bacteriostatic water. Lyophilised peptides stored at −20°C retain full potency for 24 months, while reconstituted solutions must be refrigerated at 2–8°C and used within 14 days. Temperature excursions above 8°C denature the peptide structure irreversibly. At Real Peptides, all peptides are synthesized through small-batch production with third-party HPLC verification to confirm ≥98% purity. Impurities as low as 2% can trigger immune responses unrelated to the intended mechanism, confounding research outcomes.